140 related articles for article (PubMed ID: 32452526)
1. Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis.
Lauer EM; Waterhouse M; Braig M; Mutter J; Bleul S; Duque-Afonso J; Duyster J; Marks R; Reinacher PC; Prinz M; Illerhaus G; Finke J; Schorb E; Scherer F
Br J Haematol; 2020 Jul; 190(2):e110-e114. PubMed ID: 32452526
[No Abstract] [Full Text] [Related]
2. Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
Renaud L; Bossard JB; Carpentier B; Terriou L; Cambier N; Chanteau G; Escure G; Tilmont R; Barbieux S; Wemeau M; Hieulle J; Boyle EM; Morschhauser F
Eur J Haematol; 2021 Sep; 107(3):370-373. PubMed ID: 34018260
[No Abstract] [Full Text] [Related]
3. A Case of Bing-Neel Syndrome Treated Successfully With Ibrutinib Monotherapy Following Intensive Chemoimmunotherapy.
Carella M; Stefoni V; Broccoli A; Argnani L; Zinzani PL
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e817-e819. PubMed ID: 34281758
[No Abstract] [Full Text] [Related]
4. [Mantle cell lymphoma with central nervous system relapse successfully treated with nasogastric-tube administration of ibrutinib].
Okahashi N; Uchihara M; Hoshino E
Rinsho Ketsueki; 2020; 61(10):1508-1510. PubMed ID: 33162449
[TBL] [Abstract][Full Text] [Related]
5. Successful Rapid Oral Desensitization to Ibrutinib in a Patient With Severe Immediate Hypersensitivity Reaction.
Tsilimidos G; Horisberger A; Ribi C; Cairoli A; Stalder G
Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):e745-e747. PubMed ID: 34158264
[No Abstract] [Full Text] [Related]
6. Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience.
Lewis KL; Chin CK; Manos K; Casey J; Hamad N; Crawford J; Ho SJ; Issa S; Grigg A; Wood P; Gandhi MK; Do B; Nastoupil L; Hawkes EA; Cheah CY
Br J Haematol; 2021 Mar; 192(6):1049-1053. PubMed ID: 32677095
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.
Chen F; Pang D; Guo H; Ou Q; Wu X; Jiang X; Wei X; Liu S; Huang L; Liang Z; Zhou D; Li W
Cancer Med; 2020 Nov; 9(22):8676-8684. PubMed ID: 33068336
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib in primary central nervous system diffuse large B-cell lymphoma.
T Low J; B Peters K
CNS Oncol; 2020 Mar; 9(1):CNS51. PubMed ID: 32141313
[TBL] [Abstract][Full Text] [Related]
9. Prolonged remission with ibrutinib maintenance therapy following radiation in a patient with relapsed primary CNS lymphoma.
Du S; Fu DB; A Bota D; Kong XT
CNS Oncol; 2024 Jun; 13(1):2345579. PubMed ID: 38722227
[TBL] [Abstract][Full Text] [Related]
10. Central Nervous System Post-transplant Lymphoproliferative Disorder: Response to Ibrutinib.
Kallam A; Hansen N; Bierman P
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e930-e933. PubMed ID: 32782203
[No Abstract] [Full Text] [Related]
11. Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series.
Chamoun K; Choquet S; Boyle E; Houillier C; Larrieu-Ciron D; Al Jijakli A; Delrieu V; Delwail V; Morschhauser F; Hoang-Xuan K; Soussain C
Neurology; 2017 Jan; 88(1):101-102. PubMed ID: 27864520
[No Abstract] [Full Text] [Related]
12. [Combination of ibrutinib and temozolomide for the treatment of newly diagnosed elderly primary central nervous system diffuse large B cell lymphoma: a case report].
Wang L; Li X; He YZ
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):482. PubMed ID: 32654461
[No Abstract] [Full Text] [Related]
13. Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type.
Moore DC; Soni AC; Hu B; Smith ET; Levine J; Moyo TK; Jacobs R; Ghosh N; Park SI
Br J Haematol; 2022 Feb; 196(4):e30-e33. PubMed ID: 34642938
[No Abstract] [Full Text] [Related]
14. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.
Soussain C; Choquet S; Blonski M; Leclercq D; Houillier C; Rezai K; Bijou F; Houot R; Boyle E; Gressin R; Nicolas-Virelizier E; Barrie M; Moluçon-Chabrot C; Lelez ML; Clavert A; Coisy S; Leruez S; Touitou V; Cassoux N; Daniau M; Ertault de la Bretonnière M; El Yamani A; Ghesquières H; Hoang-Xuan K
Eur J Cancer; 2019 Aug; 117():121-130. PubMed ID: 31279304
[TBL] [Abstract][Full Text] [Related]
15. Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis.
Yi JH; Kim SJ; Yoon DH; Suh C; Chang MH; Yang DH; Jo JC; Hyun SY; Eom HS; Lee JO; Kwon JH; Han SH; Lee SS; Kwak JY; Kim SH; Kim DS; Lee JH; Oh SY; Ryoo HM; Kim HJ; Kim WS
Cancer Commun (Lond); 2021 Mar; 41(3):275-278. PubMed ID: 33626235
[No Abstract] [Full Text] [Related]
16. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
Grommes C; Tang SS; Wolfe J; Kaley TJ; Daras M; Pentsova EI; Piotrowski AF; Stone J; Lin A; Nolan CP; Manne M; Codega P; Campos C; Viale A; Thomas AA; Berger MF; Hatzoglou V; Reiner AS; Panageas KS; DeAngelis LM; Mellinghoff IK
Blood; 2019 Jan; 133(5):436-445. PubMed ID: 30567753
[TBL] [Abstract][Full Text] [Related]
17. Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.
Tanigawa T; Sakurai M; Kato J; Mizuno K; Fujita S; Koda Y; Kikuchi T; Shimizu T; Okamoto S; Kataoka K
Ann Hematol; 2022 Mar; 101(3):723-724. PubMed ID: 34235557
[No Abstract] [Full Text] [Related]
18. Dramatic Efficacy of Ibrutinib in a Schnitzler Syndrome Case with Indolent Lymphoma.
Claves F; Siest R; Lefebvre C; Valmary-Degano S; Carras S
J Clin Immunol; 2021 Aug; 41(6):1380-1383. PubMed ID: 33871787
[No Abstract] [Full Text] [Related]
19. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
Grommes C; Pastore A; Palaskas N; Tang SS; Campos C; Schartz D; Codega P; Nichol D; Clark O; Hsieh WY; Rohle D; Rosenblum M; Viale A; Tabar VS; Brennan CW; Gavrilovic IT; Kaley TJ; Nolan CP; Omuro A; Pentsova E; Thomas AA; Tsyvkin E; Noy A; Palomba ML; Hamlin P; Sauter CS; Moskowitz CH; Wolfe J; Dogan A; Won M; Glass J; Peak S; Lallana EC; Hatzoglou V; Reiner AS; Gutin PH; Huse JT; Panageas KS; Graeber TG; Schultz N; DeAngelis LM; Mellinghoff IK
Cancer Discov; 2017 Sep; 7(9):1018-1029. PubMed ID: 28619981
[TBL] [Abstract][Full Text] [Related]
20. A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma.
Qualls D; Lam HY; Whiting K; Kumar A; Matasar M; Owens C; Nichols C; Espeleta JA; Qiu A; Subzwari S; Biggar E; Seshan V; Salles G; Younes A; Batlevi C
Blood Adv; 2022 Sep; 6(18):5262-5266. PubMed ID: 35171976
[No Abstract] [Full Text] [Related]
[Next] [New Search]